PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28220370-0	2017	The effect of candesartan on pentraxin-3 plasma levels as marker of endothelial dysfunction in patients with essential arterial hypertension.	candesartan	14-25	pentraxin 3	Homo sapiens	29-40	
28220370-7	2017	RESULTS: The patients treated with candesartan had a significant lower value of PTX3 and hs-CRP, compared with those under treatment with other antihypertensive medication as follows: PTX3: 0.61 +- 0.49 vs 0.95 +- 1.04 ng/ml, P = 0.006 and hs-CRP: 0.19 +- 0.20 vs 0.20 +- 0.22 mg/dl, P = 0.54.	candesartan	35-46	pentraxin 3	Homo sapiens	80-84	
28220370-7	2017	RESULTS: The patients treated with candesartan had a significant lower value of PTX3 and hs-CRP, compared with those under treatment with other antihypertensive medication as follows: PTX3: 0.61 +- 0.49 vs 0.95 +- 1.04 ng/ml, P = 0.006 and hs-CRP: 0.19 +- 0.20 vs 0.20 +- 0.22 mg/dl, P = 0.54.	candesartan	35-46	pentraxin 3	Homo sapiens	184-188	
28220370-8	2017	CONCLUSIONS: Candesartan decreases PTX3 and hs-CRP plasma levels more powerful than other classes of antihypertensive drugs (beta blockers, calcium channel blockers, and diuretics), so we may assume that candesartan has a more potent action in reversing endothelial dysfunction and that it offers a higher vascular protection than other classes of antihypertensive drugs.	candesartan	13-24	pentraxin 3	Homo sapiens	35-39